[Pharmaceutical therapy of breast cancer].
Láng
István
I
Országos Onkológiai Intézet, Budapest.
Kahán
Zsuzsanna
Z
Pintér
Tamás
T
Dank
Magdolna
M
Boér
Katalin
K
Pajkos
Gábor
G
Faluhelyi
Zsolt
Z
Pikó
Béla
B
Eckhardt
Sándor
S
Horváth
Zsolt
Z
D000740:Anemia / Q000139:chemically induced / Q000628:therapy; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D002100:Cachexia / Q000209:etiology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human